Share
16,624 Posts.
lightbulb Created with Sketch. 2370
clock Created with Sketch. 08/05/24
17:47
Share
Originally posted by PigRace
↑
While I very much wish whytee being right, I would not share his optimism regarding first trial results getting reported April 2025.Eylea (aflibercept, REGN, BAY) reported topline data for two P3 trials VIEW1 and VIEW2 the same day on Nov 22, 2010 (2 months post primary completion date of the last trial having completed).Beovu (brolucizumab, NOVN) reported topline data for two P3 trials HARRIER and HAWK the same day on Jun 20, 2017 (2 months post primary completion date of the last trial having completed)Vabysmo (faricimab ROG) reported topline data for two P3 trials LUCERNE and TENAYA the same day on Jan 25, 2021 (3 months post primary completion date of the least trial having completed)May 2024 Topline results for both COAST and ShORe 2 months later = Jul 2025 Base Case (less good, but still completely in line with OPT‘s current guidance): Jun 2024 Topline results for both COAST and ShORe 3 months Sep 2025
Expand
Sorry but the trials are completely separate. They have different drugs and different recruitment centres. Recruitment was completed for the Eyelea trial in February. I don't see any reason at all to suppose that the results would be withheld until another trial was completed. The ASX rules on continuous disclosure prohibit it.
Last edited by
whytee :
08/05/24
(20min delay)